PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
19.08
+1.77 (10.20%)
Jan 22, 2026, 4:00 PM EST - Market closed
PureTech Health Employees
PureTech Health had 56 employees as of December 31, 2024. The number of employees decreased by 34 or -37.78% compared to the previous year.
Employees
56
Change (1Y)
-34
Growth (1Y)
-37.78%
Revenue / Employee
$114,125
Profits / Employee
$904,964
Market Cap
440.26M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 56 | -34 | -37.78% |
| Dec 31, 2023 | 90 | -21 | -18.92% |
| Dec 31, 2022 | 111 | 16 | 16.84% |
| Dec 31, 2021 | 95 | -155 | -62.00% |
| Dec 31, 2020 | 250 | -50 | -16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 650 |
| Rocket Pharmaceuticals | 299 |
| Entrada Therapeutics | 183 |
| Assembly Biosciences | 73 |
| Contineum Therapeutics | 41 |
| Eupraxia Pharmaceuticals | 33 |
| Zura Bio | 30 |
| DiaMedica Therapeutics | 28 |
PRTC News
- 7 days ago - PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 5 weeks ago - PureTech Appoints Robert Lyne as Chief Executive Officer - Business Wire
- 6 weeks ago - PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis - Business Wire
- 6 weeks ago - PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Business Wire
- 3 months ago - PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group - Business Wire
- 4 months ago - PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF - Business Wire
- 5 months ago - PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha